Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2024 Oct;84(10):1313-1318. doi: 10.1007/s40265-024-02087-4. Epub 2024 Sep 6.
Donanemab (donanemab-azbt; Kisunla) is an amyloid β-directed antibody developed by Eli Lilly and Company for the treatment of Alzheimer's disease. Donanemab recently received approval in the USA for the treatment of adults with early symptomatic Alzheimer's disease (patients with mild cognitive impairment or mild dementia stage of disease). This article summarizes the milestones in the development of donanemab leading to this first approval for Alzheimer's disease.
多纳单抗（donanemab-azbt；Kisunla）是由礼来公司开发的一种针对淀粉样β的抗体，用于治疗阿尔茨海默病。多纳单抗最近在美国获得批准，用于治疗早期有症状的阿尔茨海默病患者（轻度认知障碍或疾病轻度痴呆阶段的患者）。本文总结了导致多纳单抗首次获批用于阿尔茨海默病的开发历程中的重要里程碑。
